Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
Clene (CLNN) Stock Price & Analysis
866 Followers
CLNN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.23 - $16.10
Previous Close$4.33
Volume38.05K
Average Volume (3M)38.16K
Market Cap
$28.89M
Enterprise Value$19.77M
Total Cash (Recent Filing)$35.00M
Total Debt (Recent Filing)$26.90M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 12, 2024EPS Estimate
-$1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding128,433,721
10 Day Avg. Volume864,363
30 Day Avg. Volume38,164
Standard Deviation0.30
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)3.80
Price to Sales (P/S)77.83
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.80
Enterprise Value/Gross Profit37.09
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$26.75Price Target Upside495.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Clene News
PremiumCompany Announcements
Clene Announces Reverse Stock Split and Share Structure Changes
PremiumPress Releases
Clene Announces 1-for-20 Reverse Stock Split
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company's investigational drug, CNM-Au8, has shown significant improvements in visual amplitude in study participants.
Financial PerformanceThe company ended the year with $35 million in cash, which management believes provides runway to fund ongoing operations.
Market OpportunityThe potential removal of Relyvrio opens a significant opportunity for CNM-Au8 in the ALS therapy market.
Bears Say
EarningsClene reported 1Q24 results with a net loss of ($11.1M), and ended the period with $27.9M in cash & equivalents.
Financial PerformanceFinancial results posted EPS of ($0.08) and ($0.47), respectively, missing both the company's estimates and consensus.
RegulatoryFDA feedback indicated that the existing neurofilament light chain (NfL) data is insufficient for an accelerated NDA filing under an accelerated approval pathway.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $4.23 and its highest was $16.10 in the past 12 months.
What is Clene’s market cap?
Currently, no data Available
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on May 08, 2024. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.6 by -$0.2.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -$1.5.
How many shares outstanding does Clene have?
Clene has 6,435,000 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.6. Following the earnings report the stock price went down -0.383%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.75 (495.77% Upside)
$26.75 (495.77% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $13.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.53%
12-Months-Change
Fundamentals
Return on Equity
-3702.24%
Trailing 12-Months
Asset Growth
12.99%
Trailing 12-Months
Company Description
Clene
Clene is a clinical-stage biopharma company focused on developing and commercializing nanotherapeutics for the treatment of neurodegenerative disease.
---
CLNN Stock 12 Month Forecast
Average Price Target
$26.75
▲(495.77% Upside)
Technical Analysis
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-53.56%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.56% per trade.
---